Blocking a key enzyme boosts anticancer T-cell responses and resistance to immunosuppression, according to a mice study from LSU Health New Orleans published August 26 in Frontiers in Immunology.  

A combination of oncolytic virotherapy, a technique using cancer-fighting viruses, acting in concert with immunotherapy shows promise for treatment-resistant cancers, according to new research.  

A combination of oncolytic virotherapy, a technique using cancer-fighting viruses, acting in concert with immunotherapy shows promise for treatment-resistant cancers, according to new research.  

Georgia State University researchers have discovered a new way to treat ulcerative colitis -- oral delivery of lipid nanoparticles that target the colon with nucleic acids.  

The W.M. Keck Foundation has awarded a $1.2 million grant to researchers at the University of Chicago and the University of Kansas to help identify human gene sequences that will respond to drug therapies.  

Scientists have discovered 15 instances in which new mucins appear to have evolved through an additive process that transformed a nonmucin protein into a mucin.  

Blocking a key enzyme boosts anticancer T-cell responses and resistance to immunosuppression, according to a mice study from LSU Health New Orleans published August 26 in Frontiers in Immunology.  

Researchers at Karolinska Institutet in Sweden have developed a new type of treatment for chronic hepatitis B virus and hepatitis D virus infections that may provide a lasting treatment response.  

The plant protein ribulose-1,5-bisphosphate carboxylase-oxygenase (rubisco) is an enzyme that adopts multiple assemblies, according to new research from the Lawrence Berkeley National Lab in Berkeley, CA. However, the origins and distribution of its different oligomeric states remain mysterious.